Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-3150 Safety in Japanese Type 2 Diabetic Patients with Macroalbuminuria
jRCT2080223640Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esaxerenone in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis, macroalbuminuria and 1 more, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability of esaxerenone (CS-3150). Started Sep 2017; status: completed.
02
Drugs
esaxerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosismacroalbuminuriahypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223640.